Comprehensive Diabetic Neuropathy Pipeline Insight Report for 2024 Reveals Progress in Treatment Landscape [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
An in-depth pipeline insight report has been released, offering a comprehensive overview of the ongoing research and development of treatments for Diabetic Neuropathy. The report delves into detailed profiles of therapeutics currently under clinical and nonclinical stages, assessing over 20 companies and 25 pipeline drugs. Understanding Diabetic Neuropathy Diabetic Neuropathy, a nerve damage condition associated with diabetes, presents a significant challenge due to its complex symptoms that affect millions worldwide. The report aims to furnish a thorough understanding of the disease, its symptoms, causes, and current treatment approaches. Emphasizing the importance of innovation in therapeutic development, the insight highlights novel drug candidates and their potential to transform the treatment landscape of Diabetic Neuropathy. Emerging Therapeutic Drugs and Therapeutic Assessment Key sections of the report offer a scrutinizing look at emerging drugs, providing analyses of
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Coherus offloads Humira biosimilar Yusimry for $40m [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Argus from $300.00 to $340.00. They now have a "buy" rating on the stock.MarketBeat
- Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications [Yahoo! Finance]Yahoo! Finance
- Global Pharmaceutical Marketing Industry Research Report 2024-2030: Market Size Projections for Conference Marketing, PPC Advertising, Print Advertising, Social Media Campaigns, TV Commercials, and More [Yahoo! Finance]Yahoo! Finance
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 6/21/24 - Form 11-K
- 6/21/24 - Form 11-K
- 6/12/24 - Form S-8
- AMGN's page on the SEC website